Blueprint Medicines [BPMC] vs Vertex [VRTX] Detailed Stock Comparison

Blueprint Medicines Corp.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Blueprint Medicines Corp. wins in 2 metrics, Vertex Pharmaceuticals Inc. wins in 17 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Blueprint Medicines Corp. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) -120.99 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 24.43 5.92 Vertex Pharmaceuticals Inc.
Debt-to-Equity Ratio 208.50 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -137.72 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -53.14 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) -27.70% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -27.50% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -47.71% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -9.75% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-197.22M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 12.60% 1.24% Blueprint Medicines Corp.
Price-to-Sales Ratio (TTM) 14.89 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $8.42B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 14.97 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) 98.12% 85.39% Blueprint Medicines Corp.
Revenue per Share (TTM) $9 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-2.51 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.83 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 5.45% 1.78% Vertex Pharmaceuticals Inc.

Blueprint Medicines Corp. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

BPMC
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Blueprint Medicines Corp.0.00%0.12%1.05%53.79%61.42%61.42%
Vertex Pharmaceuticals Inc.0.76%-2.49%-1.11%-12.54%-1.86%-5.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Blueprint Medicines Corp.12.60%149.54%73.38%370.76%598.65%598.65%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Blueprint Medicines Corp. vs Vertex Pharmaceuticals Inc.

MetricBPMCVRTX
Market Information
Market Cap i$8.37B$109.45B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i5,799,9401,057,061
90 Day Avg. Volume i4,343,3571,272,097
Last Close$129.46$428.34
52 Week Range$73.04 - $129.65$362.50 - $507.92
% from 52W High-0.15%-15.67%
All-Time High$129.65 (Jul 16, 2025)$519.88 (Nov 04, 2024)
% from All-Time High-0.15%-17.61%
Growth Metrics
Quarterly Revenue Growth0.56%0.10%
Quarterly Earnings Growth-0.99%0.31%
Financial Health
Profit Margin (TTM) i-0.28%0.33%
Operating Margin (TTM) i-0.28%0.40%
Return on Equity (TTM) i-0.48%0.23%
Debt to Equity (MRQ) i208.5010.91
Cash & Liquidity
Book Value per Share (MRQ)$5.30$73.49
Cash per Share (MRQ)$8.92$26.01
Operating Cash Flow (TTM) i$-145,552,000$3.63B
Levered Free Cash Flow (TTM) i$-20,779,750$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Blueprint Medicines Corp. vs Vertex Pharmaceuticals Inc.

MetricBPMC (Aug 03, 2025)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-120.9928.40
Forward P/E i-137.7219.95
PEG Ratio i-137.720.88
Price to Sales (TTM) i14.899.22
Price to Book (MRQ) i24.435.92
Market Capitalization
Market Capitalization i$8.37B$109.45B
Enterprise Value i$8.42B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i14.978.83
Enterprise to EBITDA i-53.1421.78
Risk & Other Metrics
Beta i0.830.37
Book Value per Share (MRQ) i$5.30$73.49

Financial Statements Comparison: Blueprint Medicines Corp. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBPMC (2024)VRTX (2025)
Revenue/Sales i508.82M12.00B
Cost of Goods Sold i20.16M1.65B
COGS % of Revenue i4.0%13.8%
Gross Profit i488.66M10.35B
Gross Margin i96.0%86.2%
Research & Development i341.43M4.04B
Operating Income (EBIT) i-212.04M4.55B
Operating Margin i-41.7%37.9%
EBITDA i-154.44M5.25B
EBITDA Margin i-30.4%43.7%
Pre-Tax Income i-65.86M4.64B
Pre-Tax Income % of Revenue i-12.9%38.7%
Income Tax i1.23M690.00M
Income Tax % of Revenue i0.2%5.7%
Net Income (Profit) i-67.09M3.95B
Profit Margin i-13.2%32.9%

Balance Sheet & Liquidity Metrics

MetricBPMC (2024)VRTX (2025)
Cash & Equivalents i102.01M5.08B
Total Current Assets i742.68M11.20B
Total Current Assets % of Revenue i146.0%93.3%
Total Current Liabilities i260.80M3.86B
Total Current Liabilities % of Revenue i51.3%32.2%
Long-Term Debt i411.84M1.95B
Long-Term Debt % of Revenue i80.9%16.3%
Total Shareholders Equity i298.67M18.67B
Retained Earnings i-2.41B13.56B
Retained Earnings % of Revenue i-473.1%113.0%
Property, Plant & Equipment i89.90M1.56B

Cash Flow Statement Comparison

MetricBPMC (2024)VRTX (2025)
Operating Cash Flow i-2.02M3.77B
Operating Cash Flow % of Revenue i-0.4%31.4%
Capital Expenditures i-4.63M-437.60M
Free Cash Flow i-197.22M3.19B
FCF Margin i-38.8%26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricBPMCVRTX
Shares Short i3.13M4.02M
Short Ratio i0.622.80
Short % of Float i5.45%1.78%
Shares Outstanding i63.71M253.99M
Float Shares i60.00M253.24M
% Held by Insiders i0.88%0.21%
% Held by Institutions i109.19%97.60%
% Held by Public i-10.07%2.19%

Dividend Analysis & Yield Comparison: Blueprint Medicines Corp. vs Vertex Pharmaceuticals Inc.

MetricBPMCVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A